Buformin suppresses the expression of glyceraldehyde 3-phosphate dehydrogenase.
The biguanides metformin and buformin, which are clinically used for diabetes mellitus, are known to improve resistance to insulin in patients. Biguanides were reported to cause lactic acidosis as a side effect. Since the mechanism of the side effect still remains obscure, we have examined genes whose expression changes by treating HepG2 cells with buformin in order to elucidate the mechanisms of the side effect. A subtraction cDNA library was constructed by the method of suppressive subtractive hybridization and the screening of the library was performed with cDNA probes prepared from HepG2 cells treated with or without buformin for 12 h. The expression of the gene and the protein obtained by the screening was monitored by real-time RT-PCR with specific primers and Western blotting with specific antibody. The amounts of ATP and NAD+ were determined with luciferase and alcohol dehydrogenase, respectively. We found that expression of the glyceraldehyde 3-phosphate dehydrogenase (GAPD) gene was suppressed by treating HepG2 cells with 0.25 mM buformin for 12 h as a result of the library screening. The decrease in the expression depended on the treatment period. The amount of GAPD protein also decreased simultaneously with the suppression of the gene expression by the treatment with buformin. The amount of ATP and NAD+ in the HepG2 cells treated with buformin decreased to 10 and 20% of the control, respectively. These observations imply that the biguanide causes deactivation of the glycolytic pathway and subsequently the accumulation of pyruvate and NADH and a decrease in NAD+. Therefore, the reaction equilibrium catalyzed by lactate dehydrogenase leans towards lactate production and this may result in lactic acidosis.
Yano
Akiko
A
Department of Pharmaceutics, Gifu Pharmaceutical University, Japan.
Kubota
Masafumi
M
Iguchi
Kazuhiro
K
Usui
Shigeyuki
S
Hirano
Kazuyuki
K
D000140:Acidosis, Lactic / Q000139:chemically induced / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000096:biosynthesis; D015153:Blotting, Western; D002026:Buformin / Q000494:pharmacology*; D002460:Cell Line; D018076:DNA, Complementary / Q000096:biosynthesis; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000037:antagonists & inhibitors* / Q000096:biosynthesis*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D009243:NAD / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
D018076:DNA, Complementary; D007004:Hypoglycemic Agents; D009243:NAD; D000255:Adenosine Triphosphate; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D002026:Buformin